Medytox Inc. is a biopharmaceutical company that focuses on developing
innovative biotech products necessary to diagnose and treat various diseases.
As the world¡¯s fourth developer of Botulinum Toxin products, Medytox
provides its botulinum toxin type A complex, ¡°Neuronox,¡± to a host of
customers and partners in more than 30 countries, including Japan, India and
Brazil as well as in Korea.
Neuronox, which has the same composition as the first Botulinum Toxin
product developed by a U.S. company with 80% of market share in the global
market, is used for therapeutic purposes to treat such diseases as
Blepharospasm and cerebral palsy as well as for cosmetic purposes.
Neuronox has undergone many successful preclinical and clinical studies for several years. The test results
have proven that Neuronox has excellent efficacy in both therapeutic and cosmetic uses.
|